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Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening disease caused by cytokine storm-
induced severe inﬂammation, and malignant lymphoma is the leading cause of HLH in adults. We
herein have reported the case of a 28-year-old man afﬂicted with subcutaneous panniculitis-like T cell
lymphoma who presented to our facility complaining of fever, cough and myalgia for one week.
Following an examination, the patient was diagnosed with hemophagocytic lymphohistiocytosis ac-
cording to the diagnostic criteria of HLH 1994 protocol published in 1997. Treatment with the HLH 1994
protocol (chemotherapy with etoposide combined with steroid based regimen) was initiated and the
patient recovered well. However, subcutaneous panniculitis-like T cell lymphoma was diagnosed by neck
soft tissue biopsy nine months later. Thereafter, this patient then received chemotherapy using the
ESHAP regimen for one cycle (etoposide 40 mg/m2 BSA, cisplatin 25 mg/m2 BSA and methylprednisolone
500 mg at day 1 to day 4, and cytarabine 2000 mg/m2 at day 5). Currently, this patient continues his
regular follow-up at our hematologic outpatient department.
Copyright © 2016, The Chinese Oncology Society. Production and hosting by Elsevier B.V. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Hemophagocytic lymphohistiocytosis (HLH), also known as
hemophagocytic syndrome (HPS), is a life-threatening disease
caused by extreme inﬂammation. It is believed that uncontrolled
activated lymphocytes and macrophages proliferation result in a
cytokine storm, which is responsible for this critical clinical sce-
nario. Etiologies of HLH are different in pediatric and adult pa-
tients. Primary HLH (as observed in familial HLH), X-linked
lymphoproliferative syndrome, and ChediakeHigashi syndrome or
viral infections, are common causes of HLH in pediatric patients.1gy and Medical Oncology,
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ncology Society.
Society. Production and hosting byOn the other hand, malignancies are the leading causes of HLH in
adults, particularly malignant lymphoma.2 The most common-
place presenting signs and symptoms of HLH are fever, hep-
atosplenomegaly, and cytopenias. This immune dysregulatory
disorder is prominently associated with cytopenias and clinical
signs and symptoms of extreme inﬂammation. Prompt initiation of
immunochemotherapy is essential for survival, but timely diag-
nosis may be challenging.3 Among all the possible etiologies,
malignant lymphoma is the predominant cause of HLH in adults.
In 1991, Gonzalez et al4 described a new type of T-cell lymphoma
with clinicopathological features simulating panniculitis. This new
type of T-cell lymphoma had an aggressive clinical course and was
often presenting with HLH. Herein, we reported a patient with
subcutaneous panniculitis-like T cell lymphoma-associated HLH,
although his underlying lymphoma was not diagnosed until nine
months later.Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
Fig. 2. Bone marrow aspiration (at initial diagnosis). Bone marrow smear showed that
neutrophils are found within the cytoplasm of histiocyte (arrow), indicating
hemophagocytosis.
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A 28-year-old man visited our emergency department because
of intermittent fever, dry cough, and myalgia for one week. Ac-
cording to the patient, he had a generally unremarkable prior
health history, and denied history of hepatitis or any other systemic
diseases; he also denied alcohol drinking. In addition to the com-
plained of fever and cough, the patient also described night
sweating and body weight loss. However, local clinical information
revealed the patient suffered from leukopenia and impaired liver
function. Furthermore, our hospital laboratory data revealed
leukopenia (leukocyte: 1600/mL; normal range: 3900e10,600),
anemia (hemoglobin: 12.4 g/dL; normal range: 13.5e17.5), and
thrombocytopenia (platelet: 108  103/uL; normal range:
150e400). Liver function tests showed elevated GOT (aspartate
aminotransferase): 364 U/L; normal range: 8e38, and GPT (alanine
aminotransferase): 235 U/L; normal range: 10e50. Abnormal LDH
(lactate dehydrogenase) (2212 U/L; normal range: 120e240) was
also found. The patient's abdominal computed tomography scan
indicated only splenomegaly, with normal liver and gallbladder
appearance (Fig. 1). In addition, hyperferritinemia: 59,384 ng/ml,
low ﬁbrinogen: 139.3 mg/dl and increased cell free IL-2R (inter-
leukin-2 receptor): 1155.4 pg/ml were noted. A Gallium-67 scan
revealed no evidence of gallium-avid tumor. The possible causes of
fever were evaluation, including EBV infection, HSV, CMV or HIV
and rheumatologic disease, but all of the above generated negative
results. With a preliminary diagnosis of HLH, the patient then
received a bone marrow examination which showed hypercellular
marrow with increased inﬁltration of histiocytes and profound
hemophagocytosis (Fig. 2). After treatment by HLH 1994 protocol
(chemotherapy with etoposide combined with steroid based
regimen),5 the patient's fever subsided and liver function
improved. After that, the patient further underwent three cycles of
chemotherapy with weekly etoposide.
However, 10 days after he completed the last chemotherapy
round with etoposide, the patient again visited our emergency
department manifesting a fever. Lab data reported leukopenia,
anemia, and elevated LDH (leukocyte:3600/mL, hemoglobin:10.9 g/
dL, platelet:168  103/mL, and LDH:498 U/L). Thereafter,Fig. 1. CT, Abdomen (at initial diagnosis). 1. Mild splenomegaly. 2. No abnormal
lymphadenopathy in retroperitoneum or pelvis.pneumocystis jirovecii pneumonia was strongly suspected due to
the patient's chest X-ray and clinical presentation. After the anti-
biotic Sevatrim was administered (Trimethoprim 80 mg/Sulfa-
methoxazole 400 mg), the patient's fever subsided. At the same
time, steroidmedicationwas discontinued to avoid occult infection.
Six weeks later, the patient's fever recurred, and subsequent
examination again noted progressive leukopenia, thrombocyto-
penia, and elevated LDH. Repeated bone marrow examination
further revealed hypocellular marrow with hemophagocytosis.
Therefore, the patient received two cycles of weekly etoposide.
Follow-up lab data showed improved leukopenia and decreased
LDH, after which he then received another ﬁve cycles of weekly
etoposide. Unfortunately, induration over the bilateral cheek with
skin erythematous change and progressive facial swelling was
found. Lab data indicated recurred leukopenia (1700/mL) and
elevated LDH (729 U/L). A CT scan of the nasopharynx reported an
increased inﬁltration and swelling over the bilateral face, sub-
mandibular region and submental region. Furthermore, several
neck lymph nodes were noted, and PET (positron emissionFig. 3. Pet whole body scan (9 months after diagnosis of HLH). 1. Tumor involvement at
the bilateral upper neck (level II), posterior portion of the bilateral lower neck (level V),
left upper mediastinum, abdomen (mesentery), left para-aortic region, left iliac region
and left deep inguinal region (Grade 3). 2. The increased FDG uptake at the superﬁcial
soft tissue of the face, anterior neck, posterior neck, bilateral upper chest wall, left
upper back, right lateral abdominal wall and bilateral ﬂank, the posterior portion of the
bilateral abdominal wall (Grade 2).
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upper neck and posterior portion of the bilateral lower neck (Fig. 3).
Thus, the patient received an incisional biopsy of the upper neck
soft tissue, which showed panniculitis-like (Fig. 3) T-cell lymphoma
and immunohistochemistry stain and showed CD3(þ), CD20(),
CD56(), CD4(), CD8(þ), TIA-1(þ) and EBER() in-situ hybridi-
zation stain. Repeated bonemarrow biopsy revealed no evidence of
lymphoma bone marrow involvement. After treatment with
chemotherapy using an ESHAP regimen (etoposide 40 mg/m2 BSA,
cisplatin 25mg/m2 BSA andmethylprednisolone 500mg at day 1 to
day 4 and cytarabine 2000 mg/m2 at day 5), his symptoms and
ferritin level improved (Fig. 4). However, the lymphoma response
requires additional image evaluation at a later date.3. Discussion
Hemophagocytic lymphohistiocytosis (HLH) occurring as a pri-
mary or acquired disorder is a condition of uncontrolled immune
system stimulation. Clinical manifestations include fever, organ
enlargement, and weight loss. Additionally, laboratory tests
customarily show bicytopenia or pancytopenia, cytolysis and
cholestasis, serum ferritin elevation, and clotting disorders.6
Inherited forms of HLH produce symptoms in early childhood and
can be fatal in the absence of speciﬁc treatment. In adults, the
clinical spectrum ranges from mild and self-limited hemophago-
cytic lymphohistiocytosis to rapidly fatal multi-organ failure.
However, many questions remain unresolved regarding the diag-
nosis and treatment in adults. Hematologic malignancies may be
the main disease associated with hemophagocytic syndrome in
adults. These patients have elevated early mortality, and the un-
derlying diseases profoundly inﬂuenced the outcome.7
According to the HLH-2004 trial, HLH is diagnosed if ﬁve of the
following eight ﬁndings are present: feverS38.5 C, splenomegaly,
peripheral blood cytopenia, hypertriglyceridemia and/or hypoﬁ-
brinogenemia, hemophagocytosis in the bone marrow, spleen,
lymph node, or liver, low or absent NK cell activity, elevated ferritin,
and elevated soluble CD25 (soluble IL-2 receptor alpha).7,8 Our
patient had fever, splenomegaly, cytopenia, hypertriglyceridemia
and hypoﬁbrinogenemia, hemophagocytosis in bone marrow,
elevated ferritin and elevated soluble IL-2 receptor alpha. Initially,
there was no evidence of malignancy according to both the
lymphadenopathy and the initial bone marrow involvement. Thus,
only HLH was diagnosed.
Regarding the treatment of HLH with HLH-1994, the estimated
3-year probability of survival overall was 55%.9 According to a
previous comprehensive review study, ferritin level may provide a
prognostic marker, and regular ferritin measurements may be
useful in predicting outcomes in HLH patients.10 Our patient was
treated with HLH-1994 protocol, and his ferritin dosage decreased
from 59384 ng/ml to 3653 ng/ml. More importantly, his fever and
cytopenia improved after the treatment.0
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Fig. 4. Ferritin level during treatment course.Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is an
uncommon type of skin lymphoma. The natural history, optimal
treatment strategy, and prognostic factors associated with this
malignancy are not well-deﬁned. Rein Willemze et al identiﬁed
one hundred ﬁfty-six patients with SPTCL.11 Hemophagocytic
syndrome (HPS) was a presenting feature in 37% of patients, and
>90% of patients required treatment at diagnosis. In our patient,
he was ﬁnally diagnosed as panniculitis-like T cell lymphoma
conﬁrmed by a soft tissue incisional biopsy in which immuno-
histochemistry stain showed CD3(þ), CD20(), CD56(), CD4(),
CD8(þ), TIA-1(þ) nine months after initial diagnosis of HLH.
However, according to the recent World Health Organ-
izationeEuropean Organization for Research and Treatment of
Cancer classiﬁcation (WHO-EORTC), there has been a redeﬁnition
of the diagnostic criteria of subcutaneous panniculitis-like T-cell
lymphoma to primary cutaneous T-cell lymphoma expressing a/b
T-cell receptor (TCR) phenotype. We were limited in our ability
to make further differential diagnosis of a/b or g/d TCR pheno-
type of primary cutaneous T-cell lymphoma because there were
no available tests for TCR gene rearrangement.12 Thus, this pa-
tient's ﬁnal diagnosis of subcutaneous panniculitis-like T cell
lymphoma was based on the pathologic report and clinical
presentation.
S.R. Hoque et al reported two subsets of SPTCL: those derived
from gamma-delta T cells which carry a poor prognosis, and are
usually CD56 positive, and a more indolent group derived from
alpha-beta T cells.13 In this study, two patients were CD56 positive,
and both developed the hemophagocytic syndrome. Our patient
belonged to the CD56 negative.
Guenova E et al reported treatment with systemic corticoste-
roids induced a complete remission in patients with SPTCL.14 With
our patient, he received steroid therapy using the HLH-1994 pro-
tocol, which may assist treatment of SPTCL. In addition to steroid
therapy, chemotherapy can also be beneﬁcial for SPTCL patients. Zhi
Li Hu et al reported treatment with combination chemotherapy of
cyclophosphamide, doxorubicin, vincristine, and prednisolone can
be efﬁcacious for a 12-year-old Chinese boy who was diagnosed
with subcutaneous panniculitis-like T-cell lymphoma who pre-
sented withmultiple indolent erythematous subcutaneous nodules
on both extremities.15 Avninder Singh et al reported a successful
regression in skin lesions and constitutional symptoms in a 22-
year-old woman diagnosed as SPTCL, who presented with variably
sized multiple nodules on both legs after ﬁve cycles of a cyclo-
phosphamide, doxorubicin, vincristine and prednisone (CHOP)
regimen.16 In addition, Yu et al reported that allogeneic hemato-
poietic stem cell transplantation could possibly provide survival
beneﬁts to T-cell lymphoma-associated HLH by graft-versus-
lymphoma effect.17
With our patient, owing to the initial presentationwith HLH, we
applied aggressive treatment with etoposide-based chemotherapy
with ESHAP regimen. Currently, the patient has no fever or other
constitution symptoms. His medical plan includes a regular follow-
up and review of clinical presentation including skin and subcu-
taneous lesion and constitution symptoms and laboratory data.
In conclusion, the underlying disease leading to HLH is crucial
to each patient's treatment and outcome. However, not all pa-
tients' underlying disease can be identiﬁed when hemophagocytic
lymphohistiocytosis is diagnosed. Similar to our patient, subcu-
taneous panniculitis-like T-cell lymphoma may present initially
with hemophagocytic syndrome without evidence of other etiol-
ogy. While the optimal treatment of HLH remains controversial,
current treatment regimes usually involve high dose corticoste-
roids, etoposide or cyclosporin. The HLH-1994 protocol is
considered useful for treatment of hemophagocytic lymphohis-
tiocytosis, but corticosteroid administration is often found to be a
Y.-K. Chen et al. / Journal of Cancer Research and Practice 3 (2016) 80e83 83risk factor attributed to developing PjP in these patient pop-
ulations.18e20 The threshold of “how much for how long”
regarding steroids and risk for PjP is unknown.19 Thus more
speciﬁc treatment for underlying disease like SPCTL may be the
most important future consideration.
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